Catch the latest updates from Australia's premier stock exchange & market indices.
March 29 (Reuters) - Bioporto A/S:
* BIOPORTO ANNOUNCES FINANCIAL GUIDANCE FOR 2023
* SEES FY23 REVENUE BETWEEN APPROXIMATELY DKK 30 MILLION TO 33 MILLION
* WHILE FDA APPROVAL IS PENDING, COSTS RELATED TO FUTURE CLINICAL STUDIES ARE ASSUMED TO BE LOWER THAN IN 2022
* SEES 2023 ADJUSTED EBITDA LOSS OF APPROXIMATELY DKK 60 MILLION TO DKK 65 MILLION Source text for Eikon: Further company coverage:
The above content is directly sourced from Reuters under a contractual arrangement. The content is being provided as a convenience and for informational purposes only; and does not constitute an endorsement or approval by Kalkine Media of any of the products, services, or opinions of the organization or individual. The user is apprised that Kalkine Media bears no responsibility for the accuracy, legality, or content of Reuters, any external sites, or for that of subsequent links. The user is requested to contact Reuters directly for answers to questions regarding the content. Please note that Kalkine Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
